In high-risk prostate cancer, patients staged with PSMA-PET showed longer time before biochemical relapse! @EurUrolOncol @Uroweb @APCCC_Lugano @OncoAlert @Albert0Briganti DOI: 10.1016/j.euo.2025.11.011

Can’t think of anyone more deserving. From first-hand experience, I can attest that the expertise she brings to the podium translates into compassionate and thoughtful care at the bedside. Bravo Dr. Tolaney!

After years of decline, cases now grow 3% each year, mainly advanced disease. Black men still face double the death rate. We must improve early detection without repeating the harms of overdiagnosis. Equity saves lives, too. @OncoAlert @APCCC_Lugano @billdahutmd

Real-world data from @DeptVetAffairs helps to understand trends and inform practice. Survival in metastatic prostate cancer is increasing, likely due to use of androgen receptor pathway inhibitors. Now we show no difference in OS between abiraterone and enzalutamide @HarshrajL

🎉 Congratulations Team North America on winning the UroAmigos Ryder Cup 2025!! 🏆🇺🇸 Fantastic energy, great discussions, and an incredible showing all around. #UroAmigosLive #RyderCup2025 @montypal @brian_rini @tompowles1 @OncoAlert

Since the CHALLENGE data was reported at @ASCO & published in the @NEJM, there has been tons of discussion around the role of #exercise in #cancer. Check out my @cityofhope podcast w #LeeJonesPhD, an exercise physiologist who actually trained with the CHALLENGE authors before

Honored to endorse Dr. @neerajaiims for the @ASCO Nominating Committee (Undesignated Member). A visionary leader, dedicated mentor, and internationally recognized expert in GU oncology. He continues to shape the future of cancer research and care. #ASCOElection 🗳️

Another insightful @Uromigos Day 2 session on the evolving mHSPC landscape — from implementing today’s guidelines to shaping tomorrow’s trials. #UromigosLive @OncoAlert @urotoday

A Great Day2⃣at #UromigosLive with a Great Discussion on PARPi in #ProstateCancer with @charlesryanmd 🇺🇸and @TDorffOnc 🇺🇸 @Uromigos @tompowles1 @brian_rini @lalaniMD @AmandaNizamMD @DrKarineTawagi @nataliagandur @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas

Happening now! @brian_rini leading the discussion on evolving landscape of mHSPC @Uromigos #Uromigoslive throwing curveballs at each panelist about whether to add a 3rd agent and which one? @tompowles1 @TresUramigas @uromigosjapan

Happening now ⬇@uroamigos mHSPC landscape is transforming fast:⚡ Intensification🎯 Targeted + systemic synergies🧬 Biomarker-driven care AMPLITUDE✅ Niraparib + AAP✅ ↑ rPFS, esp. in HRR-altered mHSPC @OncoAlert @neerajaiims @brian_rini @TDorffOnc @charlesryanmd

#UroAmigosLive Day 2 is happening now — featuring an excellent debate on the role of Radioligand therapy in mHSPC. Exciting insights and great discussion from the experts @brian_rini @DrRanaMcKay Join the conversation! @ONCOALERT

Folks - we need your support! Give the video below a ❤️ to help my team (@Uromigos #TeamNorthAmerica) get a leg up in this year's competition ... great talks here from @TDorffOnc @cityofhope, @DrRosenbergMSK @MSKCancerCenter, McDermott @BIDMChealth & @kalasri3 @pmcancercentre!

Summary for those interested: Cancer care has drifted from personhood to pathology. The focus on genomics, drugs, and market-driven efficiency has devalued the relational, emotional, and existential aspects of care Dehumanization is systemic, not individual. It stems from how

Awesome to see @cityofhope's own @hoperugo taking on the role of EIC of @myESMO's journal, #ESMOOpen! @neerajaiims @DrChoueiri @VivekSubbiah @shilpaonc @BradMcG04 @DrRaviSalgia @DrMvandenBrink

Considerations for patient selection and imaging in PSMA-targeted therapy. @TDorffOnc & @JulieGr28180604 join @neerajaiims to discuss the practical challenges in radioligand therapy management. The conversation reveals significant variability in real-world practice, particularly

So excited to be at #UromigosLive this year in 🎶 Music City 🌆! Many thanks to @TDorffOnc and @KidneyCancer Mentorship Academy mentor @Brian_Rini for the opportunity 🙏

Next week! Hear from @PhillipKooMD during PCF’s free educational webinar on the power of genomic testing. Learn more & register 👉 https://t.co/87fHLdkXQs #MedEd

1/5 Our new @CellRepMed study delivers the largest #RenalMedullaryCarcinoma molecular profiling via @BostonGeneCorp + translational testing designed to uncover targetable vulnerabilities: https://t.co/TGksd8oLWM #MsaouelLab #endRMC #rarecancers

PSA screening reduces prostate cancer–specific mortality — confirmed by the strongest and longest evidence to date. 23-year ERSPC follow-up: 🔹 RR 0.87 (95% CI, 0.80–0.95) 🔹 ARR 0.22% 🔹 1 death prevented / 456 men invited It’s time for precision, not population screening. 🔗